Table 1 Baseline data in the entire study sample and the study subgroups
Entire study sample (n = 1055) | Age > 65 (n = 121) | OnabotA use (n = 185) | Daily headache (n = 347) | Chronic pain (n = 206) | Fibromyalgia (n = 101) | Treatment resistant (n = 957) | |
|---|---|---|---|---|---|---|---|
Age (years) | 50 [42–58] | 68 [66–72] | 50 [43–57] | 51 [43–59] | 51 [45–59] | 50 [43–58] | 50 [42–58] |
Female sex (n, %) | 875 (82.9%) | 89 (81%) | 164 (88.6%) | 289 (85.9%) | 183 (88.8%) | 97 (96%) | 793 (82.9%) |
Chronic migraine (n, %) | 806 (76.4%) | 94 (77.7%) | 144 (77.8%) | 333 (96%) | 166 (80.6%) | 86 (85.1%) | 740 (77.3%) |
Duration of migraine (years) | 8 [4–14] | 11 [6–20] | 6 [4–10] | 7 [4–13] | 8 [5–15] | 8 [4–15] | 8 [4–14] |
Prior number of preventives | 4 [3–5] | 4 [3–5] | 4 [3–5] | 4 [3–5] | 4 [3–5] | 4 [3–5.5] | 4 [3–5] |
Psychiatric disorders (n, %) | 346 (32.8%) | 35 (28.9%) | 75 (40.5%) | 130 (37.5%) | 124 (60.2%) | 70 (69.3%) | 308 (32.2%) |
Chronic pain (n, %) | 206 (19.5%) | 26 (21.5%) | 39 (21.1%) | 91 (26.2%) | 206 (100%) | 69 (68.3%) | 182 (19%) |
Fibromyalgia (n, %) | 101 (9.6%) | 10 (8.3%) | 28 (15.1%) | 47 (13.5%) | 69 (33.5%) | 101 (100%) | 87 (9.1%) |
Headache days per month at baseline | 20 [14–30] | 25 [15–30] | 20 [15–30] | 30 [30–30] | 27 [17–30] | 27 [20–30] | 20 [14–30] |